| Year |
Citation |
Score |
| 2022 |
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine. PMID 36097221 DOI: 10.1038/s41591-022-01959-0 |
0.303 |
|
| 2022 |
Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, Jan M, Wehrli M, Grauwet K, Horick N, Frigault MJ, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. PMID 35452603 DOI: 10.1016/j.ccell.2022.04.001 |
0.396 |
|
| 2019 |
Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, et al. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Advances. 3: 2199-2204. PMID 31324640 DOI: 10.1182/Bloodadvances.2019000445 |
0.36 |
|
| 2019 |
Jan M, Castano A, Walker A, Guirguis AA, Gasser JA, Bouffard AA, Slabicki M, Tepper A, Grinshpun DE, Kyung T, Sievers Q, Birnbaum ME, Maus MV, Ebert BL. Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors Blood. 134: 866-866. DOI: 10.1182/Blood-2019-124210 |
0.395 |
|
| 2018 |
Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP, et al. Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant Blood. 132: 817-817. DOI: 10.1182/Blood-2018-99-113911 |
0.348 |
|
| 2016 |
Jan M, Scherer F, Kurtz DM, Newman AM, Stehr H, Liu CL, Zhou L, Glover C, Advani RH, Maeda LS, Gupta NK, Levy R, Kunder CA, Sánchez-García I, Diehn M, et al. Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations Blood. 128: 4107-4107. DOI: 10.1182/Blood.V128.22.4107.4107 |
0.437 |
|
| 2015 |
Watkin LB, Jessen B, Wiszniewski W, Vece TJ, Jan M, Sha Y, Thamsen M, Santos-Cortez RL, Lee K, Gambin T, Forbes LR, Law CS, Stray-Pedersen A, Cheng MH, Mace EM, et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nature Genetics. 47: 654-60. PMID 25894502 DOI: 10.1038/Ng.3279 |
0.346 |
|
| 2015 |
Thurman AC, Davis JL, Jan M, McCulloch CE, Buelow BD. Development and validation of an app-based cell counter for use in the clinical laboratory setting. Journal of Pathology Informatics. 6: 2. PMID 25722942 DOI: 10.4103/2153-3539.150252 |
0.314 |
|
| 2013 |
Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 32: 135-40. PMID 22349821 DOI: 10.1038/Onc.2012.48 |
0.608 |
|
| 2013 |
Chung S, Pang W, Jan M, Klimek V, Weissman I, Majeti R, Park C. CD99 identifies disease stem cells in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) Experimental Hematology. 41: S16. DOI: 10.1016/J.Exphem.2013.05.060 |
0.688 |
|
| 2012 |
Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science Translational Medicine. 4: 149ra118. PMID 22932223 DOI: 10.1182/Blood.V126.23.Sci-11.Sci-11 |
0.666 |
|
| 2012 |
Chung SS, Pang WW, In GK, Jan M, Klimek VM, Melnick A, Weissman IL, Majeti R, Park CY. CD99 Identifies Disease Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes Blood. 120: 210-210. DOI: 10.1182/Blood.V120.21.210.210 |
0.599 |
|
| 2012 |
Jan M, Snyder T, Corces-Zimmerman MR, Quake S, Weissman I, Majeti R. Abstract SY35-01: Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy35-01 |
0.671 |
|
| 2012 |
Jan M, Snyder TM, Corces-Zimmerman MR, Weissman IL, Quake SR, Majeti R. Abstract 3303: Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia Cancer Research. 72: 3303-3303. DOI: 10.1158/1538-7445.Am2012-3303 |
0.672 |
|
| 2011 |
Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 108: 5009-14. PMID 21383193 DOI: 10.1073/Pnas.1100551108 |
0.701 |
|
| 2011 |
Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Research. 71: 1374-84. PMID 21177380 DOI: 10.1158/0008-5472.Can-10-2238 |
0.728 |
|
| 2010 |
Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. PMID 20813259 DOI: 10.1016/J.Cell.2010.07.044 |
0.718 |
|
| 2010 |
Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, Cha AC, Tan BT, Park CY, Levy R, Weissman IL, Majeti R. Abstract 2440: CD47 is a prognostic factor and an antibody target that synergizes with rituximab to eradicate non-Hodgkin lymphoma Cancer Research. 70: 2440-2440. DOI: 10.1158/1538-7445.Am10-2440 |
0.708 |
|
| 2009 |
Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, Levy R, Weissman IL, Majeti R. Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. Blood. 114: 2716-2716. DOI: 10.1182/Blood.V114.22.2716.2716 |
0.72 |
|
| Show low-probability matches. |